MA54923A - Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux dirigés contre des chaînes légères d'immunoglobuline et de la molécule de membrane cellulaire cd38 sur des cellules productrices d'anticorps et d'autres cellules immunitaires - Google Patents

Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux dirigés contre des chaînes légères d'immunoglobuline et de la molécule de membrane cellulaire cd38 sur des cellules productrices d'anticorps et d'autres cellules immunitaires

Info

Publication number
MA54923A
MA54923A MA054923A MA54923A MA54923A MA 54923 A MA54923 A MA 54923A MA 054923 A MA054923 A MA 054923A MA 54923 A MA54923 A MA 54923A MA 54923 A MA54923 A MA 54923A
Authority
MA
Morocco
Prior art keywords
amylodis
antibody
treatment
combination
monoclonal antibodies
Prior art date
Application number
MA054923A
Other languages
English (en)
French (fr)
Inventor
Nina Mercedes Ashton
Raymond Comenzo
Wagner Zago
Original Assignee
Prothena Biosciences Ltd
Tufts Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Tufts Medical Ct Inc filed Critical Prothena Biosciences Ltd
Publication of MA54923A publication Critical patent/MA54923A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA054923A 2019-02-12 2019-12-16 Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux dirigés contre des chaînes légères d'immunoglobuline et de la molécule de membrane cellulaire cd38 sur des cellules productrices d'anticorps et d'autres cellules immunitaires MA54923A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962804721P 2019-02-12 2019-02-12

Publications (1)

Publication Number Publication Date
MA54923A true MA54923A (fr) 2021-12-22

Family

ID=69182616

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054923A MA54923A (fr) 2019-02-12 2019-12-16 Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux dirigés contre des chaînes légères d'immunoglobuline et de la molécule de membrane cellulaire cd38 sur des cellules productrices d'anticorps et d'autres cellules immunitaires

Country Status (17)

Country Link
US (2) US20220213223A1 (https=)
EP (1) EP3923954A1 (https=)
JP (2) JP2022520572A (https=)
KR (1) KR20210143752A (https=)
CN (2) CN113924099A (https=)
AU (2) AU2019429147B2 (https=)
BR (1) BR112021015870A2 (https=)
CA (1) CA3129890A1 (https=)
CL (1) CL2021002140A1 (https=)
EA (1) EA202192235A1 (https=)
IL (1) IL285480A (https=)
JO (1) JOP20210220A1 (https=)
MA (1) MA54923A (https=)
MX (1) MX2021009687A (https=)
PH (1) PH12021551960A1 (https=)
SG (1) SG11202108767PA (https=)
WO (1) WO2020167376A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4582446A3 (en) 2019-03-05 2025-08-13 Prothena Biosciences Limited Methods of treating al amyloidosis
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
ES2914781T3 (es) * 2016-06-30 2022-06-16 Prothena Biosciences Ltd Composiciones para el tratamiento de la amiloidosis

Also Published As

Publication number Publication date
US20250075007A1 (en) 2025-03-06
WO2020167376A1 (en) 2020-08-20
KR20210143752A (ko) 2021-11-29
EA202192235A1 (ru) 2022-01-19
CL2021002140A1 (es) 2022-04-18
US20220213223A1 (en) 2022-07-07
PH12021551960A1 (en) 2022-07-18
AU2019429147A1 (en) 2021-09-09
CN113924099A (zh) 2022-01-11
WO2020167376A8 (en) 2020-10-29
JOP20210220A1 (ar) 2023-01-30
AU2019429147B2 (en) 2024-11-14
BR112021015870A2 (pt) 2021-11-03
IL285480A (en) 2021-09-30
SG11202108767PA (en) 2021-09-29
CN119950702A (zh) 2025-05-09
JP2025015588A (ja) 2025-01-30
JP2022520572A (ja) 2022-03-31
CA3129890A1 (en) 2020-08-20
EP3923954A1 (en) 2021-12-22
AU2025200997A1 (en) 2025-03-13
MX2021009687A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
MA52227A (fr) Constructions de fusion d'anticorps entrant en contact avec des cellules nk
WO2018160768A8 (en) COMPOSITIONS AND METHODS FOR INHIBITING PROTEINS SPECIFIC TO A LINE
CO6251371A2 (es) Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino
MA54923A (fr) Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux dirigés contre des chaînes légères d'immunoglobuline et de la molécule de membrane cellulaire cd38 sur des cellules productrices d'anticorps et d'autres cellules immunitaires
EA201992163A1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ
EP3849568A4 (en) ORGANOID COMPOSITIONS FOR THE PRODUCTION OF HEMATOPOIETIC STEM CELLS AND DERIVATIVES THEREOF
EP4063498A4 (en) OXA-23 TYPE CARBAPENEMASE RESISTANT HYBRIDOMA CELL LINE AND USE OF MONOCLONAL ANTIBODIES (MAB) THEREOF
UA98332C2 (ru) Гуманизированное антитело к cd44, которое опосредует цитотоксичность в отношении раковых клеток
EA202190608A1 (ru) Однодоменные анти-bcma антитела и их применение
MA43368A (fr) Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales
MY183804A (en) Humanized anti-factor d antibodies
DK2070948T3 (da) Humant Anti-CD4-antistof med immunsuppressive egenskaber
EP3768823A4 (en) METHOD OF USING ISLET CELLS
ES2013338A6 (es) Un procedimioento para la obtencion de una linea celular hibrida productora de un anticuerpo monoclonal que se une especificamente a una proteina de superficie celular de un fagocito.
ATE58554T1 (de) Menschlicher hybridomfusionspartner zur herstellung menschlicher monoklonaler antikoerper.
MX2010006181A (es) Anticuerpos monoclonales il-21 anti-humanos.
DE69721713D1 (de) Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag)
MA55797A (fr) Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19
IL307219A (en) Pluripotent stem cell-derived hematopoietic lineages
AR084263A1 (es) Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)
EP4007588A4 (en) PLANT EXOSOMES FOR THE TREATMENT OF DISEASES BY PROTEIN AGGREGATES PRODUCED IN CELLS
EP4223879A4 (en) Alpha-amylase variant
WO2023097219A3 (en) Anti-idiotype antibodies
CY1108473T1 (el) Διαγονιδιακοι ποντικοι χρησιμοποιουμενοι ως προτυπο για ανθρωπινες παθησεις οφειλομενες σε βλαστοκυτταρα
ATE556094T1 (de) Rohre für den transport von chloramin enthaltendem wasser